After more than 15 years, the battle between the Canada Revenue Agency and Glaxo Canada over the transfer price for ranitidine—the active pharmaceutical ingredient used to make the branded, anti-ulcer drug Zantac—finally reached the Supreme Court of Canada (SCC) last month.
Dr. Gene Tien joins CRA's Transfer Pricing Practice
CRA is pleased to announce that Dr. Gene Tien has joined the company as a vice president in the Transfer Pricing Practice.